U.S. Renewable Energy Stock News

Figure Technology Solutions (FIGR) is back in the spotlight after its shares reached fresh highs, helped by expectations of further Federal Reserve rate cuts and heightened attention on its new blockchain lending initiatives. See our latest analysis for Figure Technology Solutions. The recent buzz around Figure’s RWA Consortium, Solana based stablecoin launch and rate cut expectations has coincided with strong momentum, with a 7 day share price return of 32.78% and a 30 day share price return...

In early January 2026, Wix.com shares came under pressure amid a broader rotation out of technology, upcoming earnings expectations, and mixed analyst signals pointing to potential near-term underperformance despite ongoing revenue growth. At the same time, upbeat analyst commentary on Wix’s improved platform reliability and growing use for complex website projects highlighted a strengthening competitive position versus traditional alternatives like WordPress and some enterprise...

Tetra Tech (TTEK) stock is in focus after the company secured a Missile Defense Agency SHIELD indefinite delivery, indefinite quantity contract with a ceiling of US$151b, expanding its potential defense related work. See our latest analysis for Tetra Tech. The SHIELD contract headlines a busy period for Tetra Tech, with the planned CEO transition to Roger Argus and upcoming first quarter 2026 results also in focus. A 7.17% one month share price return and a 41.41% five year total shareholder...

Brightstar Lottery PLC recently announced that its subsidiary, Brightstar Global Solutions, signed a six‑year instant ticket printing and services contract with the California Lottery, awarded after a competitive procurement and granting access to its full instant ticket content, patented Infinity Instants™ technology, and support in marketing, game development, and analytics. This long-term renewal with one of the largest U.S. lotteries reinforces Brightstar’s role as a key technology...

Why Gilat Satellite Networks (GILT) Is On Investors’ Radar Now Gilat Satellite Networks (GILT) has drawn fresh attention after reporting strong third quarter 2025 earnings that exceeded analysts’ expectations and announcing a planned US$98.8 million private placement of ordinary shares at a discount. See our latest analysis for Gilat Satellite Networks. The latest move comes after Gilat’s shares touched a 52 week high of US$15.24 and sit at US$15.06 today, with a 30 day share price return of...

Extra Space Storage (EXR) is back in focus after the company promoted longtime executive Noah Springer to President on January 5, 2026. The move consolidates oversight of both strategy functions and day to day operations. See our latest analysis for Extra Space Storage. Extra Space Storage’s share price has picked up recently, with a 1 day share price return of 2.09% and a 7 day share price return of 6.28% at a last close of US$139.20. The 1 year total shareholder return of 0.77% decline and...

Morgan Stanley’s upgrade of Nurix Therapeutics (NRIX) to Overweight, alongside higher optimism from other brokers and a consensus Outperform rating, has pushed this clinical stage biotech back onto many investors’ watchlists. See our latest analysis for Nurix Therapeutics. At a share price of $19.30, Nurix has seen a 3.60% 1 day share price return and a 97.75% 90 day share price return. The 1 year total shareholder return of 5.81% contrasts with a 65.52% total shareholder return over three...

Jamf Holding overview after recent performance shift Jamf Holding (JAMF) has drawn fresh investor attention after a sharp return in the past 3 months, contrasting with weaker results over the past year and multi year period. With shares last closing at US$13.02 and a value score of 5, the stock now sits against a backdrop of modest recent revenue and net income growth, alongside an intrinsic discount estimate of 43.28%. See our latest analysis for Jamf Holding. The recent 28.28% 90-day share...

Independent Bank Corp recently showed strong operational and technical momentum, with earnings and sales growth supporting a confirmed Stage 2 uptrend that aligns with the Minervini Trend Template. This combination of improved profitability metrics and upgraded analyst expectations has drawn fresh attention to a bank typically viewed as a steady, income-oriented regional player. We’ll now examine how Independent Bank’s strong earnings and sales momentum might influence its existing...

If you are wondering whether Novanta's current share price still makes sense, you are not alone. The stock has been drawing fresh attention from investors focused on value. Novanta's share price recently closed at US$130.94, with returns of 17.8% over the last 7 days and 9.1% over the last 30 days, set against a 1 year return of an 11.2% decline and a 3 year return of a 13.0% decline. Recent news coverage has highlighted Novanta's role as a specialized technology provider across medical and...

For investors wondering whether Equinix, at around US$800 per share, is priced fairly or trading at a premium, this article examines what the current market price may indicate about the stock's value. The share price has recently closed at US$800.35, with returns of 4.7% over the past week, 9.0% over the last 30 days, 4.7% year to date, 18.0% over 3 years and 24.5% over 5 years. The 1-year return stands at a 9.0% decline. Recent attention on Equinix has largely focused on its role as a key...

If you are wondering whether Trustmark at around US$40.09 still offers value, you are not alone. This article walks through what the current price might be implying. The share price has moved 2.6% over the last week, has seen a 1.4% decline over the last month, and is up 23.9% over the past year and 52.6% over five years. This naturally raises questions about how much of the story is already reflected in the price. Recent attention on regional banks has kept investors focused on balance...

In recent weeks, VisionWave Holdings, Inc. has undergone major leadership changes, including the resignation of CEO Noam Kenig, the appointment of Douglas Davis as Interim CEO and Executive Chairman, and the addition of independent directors Mansour Khatib and Shmaya D. (Daniel) Ollech, while also facing a delayed 10-K filing. At the same time, SaverOne 2014 Ltd. announced a non-binding LOI for an RF technology collaboration that could see VisionWave pursue majority ownership in SaverOne and...

PENN Entertainment recently implemented a new corporate structure that reshapes leadership, eliminates the Executive Vice President of Operations and CIO roles, and refocuses its Interactive segment on Canadian digital assets and the Hollywood iCasino product in the U.S. A key feature of this overhaul is consolidating all retail, digital, data, cloud, and security technology under one leader to cut duplication and speed up omnichannel product development. We’ll now examine how PENN’s...

Why NOV is back on investors’ radar Interest in NOV (NOV) has picked up as several Wall Street firms reaffirm positive views on the stock, and London based Oldfield Partners lifts its ownership with a larger disclosed position. See our latest analysis for NOV. At a share price of $17.53, NOV has recently seen a 90 day share price return of 42.40% and a 1 year total shareholder return of 25.69%, suggesting momentum has picked up even though the 3 year total shareholder return of 19.51% shows a...

If you are wondering whether PotlatchDeltic at around US$43.12 is a fair deal or not, this article will walk through what the current price might be implying about value. The stock has seen returns of 8.6% over the last week, 5.5% over the last month, 8.6% year to date, 17.4% over 1 year, 10.0% over 3 years and 13.1% over 5 years. These figures may have caught the eye of investors thinking about growth potential or shifting risk. Recent coverage has focused on PotlatchDeltic as a US-listed...

Dianthus Therapeutics (DNTH) has been drawing fresh attention after its recent share price moves, prompting investors to weigh how its clinical stage autoimmune drug pipeline lines up with current revenue, losses, and recent return patterns. See our latest analysis for Dianthus Therapeutics. The recent pullback, with a 30 day share price return of a 12.37% decline and a year to date share price return of a 3.75% decline at a latest share price of $38.19, contrasts with a 1 year total...

If you are wondering whether Delta Air Lines represents good value at its current price, or if the easy gains are already behind it, this article walks you through what the numbers suggest. The stock most recently closed at US$72.31, with returns of 4.7% over the past week, 3.4% over the last month, 4.7% year to date, 9.3% over one year, 94.6% over three years and 85.9% over five years. Recent attention on the stock has centered on how investors are reassessing large US carriers and the...

Recent commentary has put Patria Investments (PAX) in focus as a growth stock, pointing to its favorable Zacks Rank, expected EPS expansion and positive earnings estimate revisions as key drivers of current investor attention. See our latest analysis for Patria Investments. Patria’s US$17.28 share price sits against a recent pattern where the 90 day share price return of 25.22% and 1 year total shareholder return of 60.40% point to momentum building around the growth story highlighted by...

In recent months, Gorman-Rupp reported record quarterly results that exceeded analyst expectations, supported by strong infrastructure-related sales and a double-digit increase in incoming orders. At the same time, renewed interest from institutional investors and a rotation toward industrial and defensive names in light of higher proposed government infrastructure and defense spending have sharpened attention on Gorman-Rupp’s order momentum and end-market exposure. We’ll now look at how...

If you are wondering whether BridgeBio Pharma's share price still reflects its underlying value after a strong run, you are not alone. The stock recently closed at US$77.25, with returns of 6.3% over the last 30 days, a 1.3% decline over the past week, and about 166% over the past year, while the 3 year return figure is very large. Recent news around BridgeBio Pharma has focused on its clinical stage pipeline, partnership activity and regulatory milestones. These factors can all influence...

CG Oncology (CGON) has drawn attention after recent share price moves, with the stock last closing at US$54.20. Investors are weighing that level against the company’s current fundamentals and recent clinical progress. See our latest analysis for CG Oncology. The latest move sits on top of strong recent momentum, with a 1 day share price return of 29.26%, a 30 day share price return of 29.85% and a 1 year total shareholder return of 79.47%. Together, these figures suggest that investors are...

Roku (ROKU) has drawn investor attention after recent share price moves, with the stock up 2.1% over the past week and 5.5% over the past month, prompting closer scrutiny of its current valuation. See our latest analysis for Roku. While the share price is now at $111.17, the recent 30-day share price return of 5.51% sits alongside a 90-day share price return of 20.81% and a 1-year total shareholder return of 40.38%, suggesting momentum has been building over the medium term even as longer...

BioStem Technologies: Recent Moves and Context for Investors BioStem Technologies (BSEM) has drawn fresh investor attention after recent trading, with the stock closing at $5.00 and showing mixed performance across the past week, month, and past 3 months. See our latest analysis for BioStem Technologies. That sharp 17.65% 1 day share price return, on top of a 27.91% year to date share price return, contrasts with a 1 year total shareholder return of a 66.67% decline. As a result, recent...